The termination of the agreements with EOFlow is a legal matter that could have been perceived negatively by the market. However, Medtronic has clarified that this will not affect their financial guidance for FY 2024, which suggests a neutral impact on the stock price. The continued development of their product pipeline could be seen as a positive signal for the company's future growth, but since this is an ongoing effort, it does not represent a new development that would significantly alter the stock's short-term trajectory.